With a great deal of negative news throughout 2020, it is worth noting a few of the remarkable achievements the year brought – in particular the advancements in Alzheimer’s disease research. Katie McDonough, director of programs and services at the Alzheimer’s Association, shares, “There are many things that we’re learning and it’s an exciting time for Alzheimer’s research.”
Listed below are just some of the Alzheimer’s discoveries that are leading us ever nearer to a cure:
- Identification of Alzheimer’s risk factors. Understanding the leading risk factors for dementia, such as pollution, excessive alcohol consumption, and traumatic brain injury (among others) is estimated to reduce cases of dementia throughout the world up to 40%.
- Falling rates of dementia cases. Over the previous 30 years, Alzheimer’s diagnoses in Europe and North America have decreased by 13% per decade – very likely as a result of lifestyle changes.
- Progress towards earlier diagnosis. The Early Detection of Neurodegenerative diseases initiative (EDoN) has been launched, whereby digital devices are being developed to diagnose dementia as early as 10 – 15 years prior to symptom onset.
- Increased attention to MCI. Mild cognitive impairment, or MCI, is currently being examined more thoroughly, making it possible for earlier strategy, diagnosis and treatment.
- Dementia blood tests. Predictors for the risk of dementia are becoming more advanced, and in a recent study from Sweden, scientists uncovered blood-based proteins that predict future memory and thinking problems.
- Review of antipsychotic prescription drugs. A recent research study conducted by the University College London revealed an elevated rate for the prescription of antipsychotic medications for those with Alzheimer’s – possibly from the increased need for delirium management as well as anxiety and agitation from COVID-19 restrictions. These meds are recommended only when no alternative is available, so decreasing their use is being explored further.
- Artificial intelligence. At a faster pace and lower cost, an innovative new AI solution is equipped to determine the formation of proteins within the brain, helping medical researchers design treatments to help remove these proteins.
- Aducanumab. The Food And Drug Administration accepted this promising drug in 2020 for a priority review process, meaning that sometime in 2021, we should find out if it’s approved for use within the general population.
At Independence-4-Seniors Home Care, we’re committed to following the most up-to-date Alzheimer’s discoveries, as well as offering the cutting-edge, highly skilled Downers Grove elderly care that helps those diagnosed with dementia live to their greatest potential. Whether the need is for full-time care, or just several hours each week for trusted respite services, reach out to us at (630) 323-4665 or online for an in-home assessment and additional details on the ways we can help. See our website for our full service area.